ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,954.50
1.59%
US Tech 100
20,332.80
1.61%
다우존스 지수
43,840.91
1.39%
Bitcoin
84,800.00
0.51%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. TransMedics Group Inc (TMDX) 시세

TransMedics Group Inc

TransMedics Group Inc (TMDX)

NASDAQ
76.32
4.20
(5.82%)
마감 01 3월 6:00AM
15분 지연
76.10
-0.22
(-0.29%)
시간외 거래: 9:21AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
76.10
매수가
75.55
매도가
76.32
거래량
2,807,928
73.00 일간 변동폭 80.22
55.00 52주 범위 177.37
market_cap
2.554B
전일 종가
72.12
개장가
73.66
최근 거래 시간
2
@
75.55
마지막 거래 시간
재정 규모
US$ 210,694,085
VWAP
75.0354
평균 볼륨(3m)
1,928,473
발행 주식
33,561,517
배당수익률
-
주가수익률
-102.37
주당순이익(EPS)
-0.75
매출
241.62M
순이익
-25.03M

TransMedics Group Inc 정보

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a porta... TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes the technology to replicate near-physiologic conditions for donor organs outside of the human body. 더 보기

섹터
Electromedical Apparatus
산업
Electromedical Apparatus
웹사이트
www.transmedics.com
본부
Andover, Massachusetts, USA
설립됨
-
TransMedics Group Inc is listed in the Electromedical Apparatus sector of the 나스닥 with ticker TMDX. The last closing price for TransMedics was US$72.12. Over the last year, TransMedics shares have traded in a share price range of US$ 55.00 to US$ 177.37.

TransMedics currently has 33,561,517 shares in issue. The market capitalisation of TransMedics is US$2.42 billion. TransMedics has a price to earnings ratio (PE ratio) of -102.37.

TransMedics (TMDX) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

약세

순 프리미엄

-10k

Calls / Puts

83.33%

매수 / 매도

150.00%

OTM / ITM

175.00%

Sweeps 비율

0.00%

TMDX 최신 뉴스

추가 뉴스

Form 8-K - Current report
Edgar (US Regulatory)
28 2월 2025
TMDX (5.82%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 2월 2025
TMDX (5.82%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 2월 2025
TMDX (5.82%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 2월 2025
TMDX (5.82%)

Form 8-K - Current report
Edgar (US Regulatory)
22 2월 2025
TMDX (5.82%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.30.39577836411675.877.7471.5012165715973.50355195CS
47.96511.69002715268.13579.99564.3138816972.75761737CS
129.2513.836948391966.8582.3755192847367.52303204CS
26-99.09-56.5614475712175.19176.3255177787689.92321704CS
52-12.33-13.943231934988.43177.37551296354100.18600061CS
15659.23351.09662122116.87177.3716.1677496083.00036651CS
26060.35383.17460317515.75177.371058252771.48855901CS

TMDX - Frequently Asked Questions (FAQ)

What is the current TransMedics share price?
The current share price of TransMedics is US$ 76.10
How many TransMedics shares are in issue?
TransMedics has 33,561,517 shares in issue
What is the market cap of TransMedics?
The market capitalisation of TransMedics is USD 2.42B
What is the 1 year trading range for TransMedics share price?
TransMedics has traded in the range of US$ 55.00 to US$ 177.37 during the past year
What is the PE ratio of TransMedics?
The price to earnings ratio of TransMedics is -102.37
What is the cash to sales ratio of TransMedics?
The cash to sales ratio of TransMedics is 10.6
What is the reporting currency for TransMedics?
TransMedics reports financial results in USD
What is the latest annual turnover for TransMedics?
The latest annual turnover of TransMedics is USD 241.62M
What is the latest annual profit for TransMedics?
The latest annual profit of TransMedics is USD -25.03M
What is the registered address of TransMedics?
The registered address for TransMedics is 200 MINUTEMAN ROAD, ANDOVER, MASSACHUSETTS, 01810
What is the TransMedics website address?
The website address for TransMedics is www.transmedics.com
Which industry sector does TransMedics operate in?
TransMedics operates in the ELECTROMEDICAL APPARATUS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
STAKSTAK Inc
US$ 3.97
(156.13%)
174.23k
ORGOOrganogenesis Holdings Inc
US$ 6.21
(102.28%)
59M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.57M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.18M
ARBBARB IOT Group Ltd
US$ 0.6635
(38.23%)
59.08M
NVNINVNI Group Ltd
US$ 0.99
(-50.50%)
72.28M
SPGCSacks Parente Golf Inc
US$ 0.2085
(-48.65%)
57.4M
ADGMAdagio Medical Holdings Inc
US$ 0.8081
(-47.53%)
756.64k
PRAXPraxis Precision Medicines Inc
US$ 38.60
(-40.64%)
3.17M
SAGSAG Holdings Ltd
US$ 1.19
(-38.97%)
788.89k
NVDANVIDIA Corporation
US$ 124.92
(3.97%)
389.48M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.44
(7.78%)
154.46M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.18M
LCIDLucid Group Inc
US$ 2.22
(-0.45%)
136.17M

TMDX Discussion

게시물 보기
Monksdream Monksdream 10 월 전
TMDX new 52+ week high
👍️0
Monksdream Monksdream 1 년 전
TMDX 10Q
👍️0
make it happen make it happen 1 년 전
Should touch $50 net lose widens, and has a 40% day. The structure shows over 100% ownership which technically should be illegal. How can there be over 100%? Imho mean institutions and whomever will be selling for a 40%ish profit overnight.
👍️0
crudeoil24 crudeoil24 4 년 전
TransMedics Late Tuesday Announced FDA Advisory Committee Panel Voted 12 To 5 That Benefits Of OCS Heart System Outweigh Risks
6:58 am ET April 7, 2021 (Benzinga) Print
TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after the review of TransMedics' clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol ("CAP") results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Heart System to the FDA's Office of Health Technology 2 (Cardiovascular Devices). The panel voted 12 to 5, with 1 abstaining, that the benefits of the OCS Heart System outweigh its risks. The panel voted 10 to 6, with 2 abstaining, that there is reasonable assurance that the OCS Heart System is effective. The panel voted 9 to 7, with 2 abstaining, that there is reasonable assurance of the OCS Heart System's safety.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
👍️0
crudeoil24 crudeoil24 4 년 전
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.
👍️0

최근 히스토리

NASDAQ
TMDX
TransMedics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지